Clinical trials have always been a very important part of the our research activities, such that the Institute is recognised as one of the most active surgical research centres of any type in Australasia, if not the world. Participation in Melanoma clinical trials is well above the NSW Health benchmark of 10% with the Institute attracting sponsors and collaborative investigator groups from all over the world.

Trials that are run at the Institute are typically multi-site and require teams of doctors, nurses, scientists, research assistants, data managers, pharmacists, and other health professionals. Trials are strictly regulated and are overseen by Ethics Committee’s comprising of representatives from both the research and general community. Click here to learn more about clinical trials.

Current clinical trials at the MIA include:

• Multicentre Selective Lymphadenectomy Trial Phase II (MSLTII)
  

• Chemosensitivity Study

• Whole Brain Radiotherapy (WBRT)

• Treat, Excise, Administer, Measure (TEAM)
  

• GSK Derma

• Vitamin D following primary treatment of melanoma at high risk of recurrence (MelD)